Can-Fite Completes Dosing of 247 Patients in Phase III Psoriasis Trial
Can-Fite BioPharma announced on November 18 that the first 247 patients in its pivotal Phase III psoriasis trial had finished treatment. The Ramat Gan-based biotechnology company said the last patient in the group designated for the prespecified interim analysis had received the final study dose. The trial is testing oral Piclidenoson for moderate-to-severe plaque psoriasis. Chief executive officer Motti Farbstein said, “We look forward to reporting the interim results in Q1 2027.” The company describes the trial as randomized, double-blind and placebo-controlled, using a protocol it says was agreed with the U.S. Food and Drug Administration and the European Medicines Agency. Participants receive either 3 mg of Piclidenoson or a placebo by mouth twice a day. The study has two main measures of efficacy at Week 16. One is the proportion of patients achieving at least a 75% improvement on the Psoriasis Area and Severity Index, known as PASI 75. The other is the proportion whose skin is rated clear or almost clear on the static Physician’s Global Assessment, corresponding to scores of zero or one. Piclidenoson is an investigational drug that acts on the A3 adenosine receptor and targets inflammatory pathways. Can-Fite reports a clinical-development safety database of more than 1,500 subjects. The company expects the Independent Data Monitoring Committee to review interim efficacy and safety results in the first quarter of 2027.

Commentary